Paul M Griffin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3188330/publications.pdf

Version: 2024-02-01

42 papers

3,111 citations

279487 23 h-index 276539 41 g-index

42 all docs 42 docs citations

times ranked

42

6122 citing authors

#	Article	IF	CITATIONS
1	Antimalarial Activity of Artefenomel Against Asexual Parasites and Transmissible Gametocytes During Experimental Blood-Stage <i>Plasmodium vivax</i> Infection. Journal of Infectious Diseases, 2022, 225, 1062-1069.	1.9	10
2	Defining the Antimalarial Activity of Cipargamin in Healthy Volunteers Experimentally Infected with Blood-Stage Plasmodium falciparum. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	16
3	A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Human Vaccines and Immunotherapeutics, 2021, 17, 1248-1261.	1.4	81
4	A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients. Contemporary Clinical Trials Communications, 2021, 23, 100830.	0.5	18
5	Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infectious Diseases, The, 2021, 21, 1383-1394.	4.6	82
6	Safety, infectivity and immunogenicity of a genetically attenuated blood-stage malaria vaccine. BMC Medicine, 2021, 19, 293.	2.3	6
7	Pharmacokinetics and Pharmacodynamics of a Proposed Pegfilgrastim Biosimilar MSB11455 Versus the Reference Pegfilgrastim Neulasta in Healthy Subjects: A Randomized, Double-blind Trial. Clinical Therapeutics, 2020, 42, 1508-1518.e1.	1.1	3
8	Phase 1â€"2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. New England Journal of Medicine, 2020, 383, 2320-2332.	13.9	1,000
9	Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study. Lancet Infectious Diseases, The, 2020, 20, 445-454.	4.6	60
10	DSM265 at 400 Milligrams Clears Asexual Stage Parasites but Not Mature Gametocytes from the Blood of Healthy Subjects Experimentally Infected with <i>Plasmodium falciparum</i> . Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	35
11	Qualitative study investigating the underlying motivations of healthy participants in phase I clinical trials. BMJ Open, 2019, 9, e024224.	0.8	23
12			
	A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2019, 64, .	1.4	43
13	Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy	1.4	20
13 14	Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2019, 64, . Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A		
	Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2019, 64, . Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I/IIa trial. PLoS ONE, 2019, 14, e0226320. Pharmacokinetic/pharmacodynamic assessment of a proposed biosimilar MSB11455 versus the currently licensed pegfilgrastim: A randomized, double-blind trial Journal of Clinical Oncology,	1.1	20
14	Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2019, 64, . Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I/IIa trial. PLoS ONE, 2019, 14, e0226320. Pharmacokinetic/pharmacodynamic assessment of a proposed biosimilar MSB11455 versus the currently licensed pegfilgrastim: A randomized, double-blind trial Journal of Clinical Oncology, 2019, 37, e14514-e14514. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli Klebsiella pneumoniae Is Bloodstream Infection and Ceftriaxone Resistance. JAMA - Journal of the</i>	0.8	20
14 15	Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2019, 64, . Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I/lla trial. PLoS ONE, 2019, 14, e0226320. Pharmacokinetic/pharmacodynamic assessment of a proposed biosimilar MSB11455 versus the currently licensed pegfilgrastim: A randomized, double-blind trial Journal of Clinical Oncology, 2019, 37, e14514-e14514. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance. JAMA - Journal of the American Medical Association, 2018, 320, 984. Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin</i>	1.1 0.8 3.8	20 1 538

#	Article	IF	CITATIONS
19	The Dynamics of Liver Function Test Abnormalities after Malaria Infection: A Retrospective Observational Study. American Journal of Tropical Medicine and Hygiene, 2018, 98, 1113-1119.	0.6	40
20	MALDI-TOF MS meets WGS in a VRE outbreak investigation. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 495-499.	1.3	18
21	Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase $1a/1b$ randomised study. Lancet Infectious Diseases, The, 2017, 17, 626-635.	4.6	108
22	First Australian case of disseminated Mycobacterium chimaera infection post-cardiothoracic surgery. Infection, Disease and Health, 2017, 22, 1-5.	0.5	8
23	Plasmodium vivax Controlled Human Malaria Infection – Progress and Prospects. Trends in Parasitology, 2017, 33, 141-150.	1.5	56
24	Safety, acceptability and tolerability of uncoated and excipient-coated high density silicon micro-projection array patches in human subjects. Vaccine, 2017, 35, 6676-6684.	1.7	34
25	A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study. Malaria Journal, 2016, 15, 469.	0.8	82
26	Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development. Antimicrobial Agents and Chemotherapy, 2016, 60, 3669-3675.	1.4	40
27	Infectivity of Plasmodium falciparum in Malaria-Naive Individuals Is Related to Knob Expression and Cytoadherence of the Parasite. Infection and Immunity, 2016, 84, 2689-2696.	1.0	14
28	An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine, COR-1. Human Vaccines and Immunotherapeutics, 2016, 12, 3079-3088.	1.4	27
29	Piperaquine Monotherapy of Drug-Susceptible <i>Plasmodium falciparum</i> Infection Results in Rapid Clearance of Parasitemia but Is Followed by the Appearance of Gametocytemia. Journal of Infectious Diseases, 2016, 214, 105-113.	1.9	55
30	Efficacy of OZ439 (artefenomel) against early <i>Plasmodium falciparum</i> blood-stage malaria infection in healthy volunteers. Journal of Antimicrobial Chemotherapy, 2016, 71, 2620-2627.	1.3	64
31	Safety and Reproducibility of a Clinical Trial System Using Induced Blood Stage Plasmodium vivax Infection and Its Potential as a Model to Evaluate Malaria Transmission. PLoS Neglected Tropical Diseases, 2016, 10, e0005139.	1.3	39
32	Acute vancomycin-resistant enterococcal bacteraemia outbreak analysis in haematology patients: a case-control study. Healthcare Infection, 2015, 20, 115-123.	0.6	5
33	Open-Label, Single-Dose, Parallel-Group Study in Healthy Volunteers To Determine the Drug-Drug Interaction Potential between KAE609 (Cipargamin) and Piperaquine. Antimicrobial Agents and Chemotherapy, 2015, 59, 3493-3500.	1.4	24
34	Vancomycin-Induced Linear IgA With Mucosal and Ocular Involvement. Infectious Diseases in Clinical Practice, 2014, 22, e119-e121.	0.1	1
35	Fasting increases serum bilirubin levels in clinically normal, healthy males but not females: a retrospective study from phase I clinical trial participants. Journal of Clinical Pathology, 2014, 67, 529-534.	1.0	8
36	Delusions of Disseminated Fungosis. Case Reports in Infectious Diseases, 2014, 2014, 1-3.	0.2	2

#	Article	IF	CITATION
37	Maldi in infection control (VRE). Pathology, 2014, 46, S45.	0.3	0
38	Experimentally Induced Blood-Stage Plasmodium vivax Infection in Healthy Volunteers. Journal of Infectious Diseases, 2013, 208, 1688-1694.	1.9	87
39	Rapid identification of VRE with MALDI-TOF MS. Pathology, 2013, 45, S57.	0.3	1
40	Chronic urticaria following acute hepatitis A. BMJ Case Reports, 2012, 2012, bcr2012006479-bcr2012006479.	0.2	6
41	Use of Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry To Identify Vancomycin-Resistant Enterococci and Investigate the Epidemiology of an Outbreak. Journal of Clinical Microbiology, 2012, 50, 2918-2931.	1.8	159
42	A Pilot Randomised Trial of Induced Blood-Stage Plasmodium falciparum Infections in Healthy Volunteers for Testing Efficacy of New Antimalarial Drugs. PLoS ONE, 2011, 6, e21914.	1.1	131